Fate Therapeutics (NASDAQ:FATE) Rating Lowered to Sell at StockNews.com
Fate Therapeutics (NASDAQ:FATE – Get Rating) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Tuesday. Other research analysts have also recently issued reports about the company. BMO Capital Markets cut Fate Therapeutics from an “outperform” rating to a “market perform” rating and lowered […]